HK1208813A1 - Diagnosis, prevention and treatment of diseases of the joint - Google Patents
Diagnosis, prevention and treatment of diseases of the jointInfo
- Publication number
- HK1208813A1 HK1208813A1 HK15109554.2A HK15109554A HK1208813A1 HK 1208813 A1 HK1208813 A1 HK 1208813A1 HK 15109554 A HK15109554 A HK 15109554A HK 1208813 A1 HK1208813 A1 HK 1208813A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diagnosis
- diseases
- prevention
- joint
- treatment
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188227 | 2012-10-11 | ||
| PCT/EP2013/070949 WO2014056915A1 (en) | 2012-10-11 | 2013-10-08 | Diagnosis, prevention and treatment of diseases of the joint |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208813A1 true HK1208813A1 (en) | 2016-03-18 |
Family
ID=47115335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15109554.2A HK1208813A1 (en) | 2012-10-11 | 2015-09-29 | Diagnosis, prevention and treatment of diseases of the joint |
| HK15110314.1A HK1209618A1 (en) | 2012-10-11 | 2015-10-20 | Diagnosis, prevention and treatment of diseases of the joint |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15110314.1A HK1209618A1 (en) | 2012-10-11 | 2015-10-20 | Diagnosis, prevention and treatment of diseases of the joint |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10980860B2 (es) |
| EP (1) | EP2906245B1 (es) |
| JP (1) | JP6355636B2 (es) |
| CN (1) | CN104755104A (es) |
| AU (2) | AU2013328774B2 (es) |
| BR (1) | BR112015007814B1 (es) |
| CA (1) | CA2885169C (es) |
| HK (2) | HK1208813A1 (es) |
| IL (3) | IL237649B (es) |
| MX (2) | MX363462B (es) |
| MY (1) | MY186106A (es) |
| RU (1) | RU2682676C2 (es) |
| SG (1) | SG11201501920PA (es) |
| WO (1) | WO2014056915A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014257748C1 (en) * | 2013-04-22 | 2019-03-07 | Ascendis Pharma A/S | Modified hydrogels |
| AU2014333953C1 (en) * | 2013-10-08 | 2020-06-25 | Ascendis Pharma A/S | Hydrogel-linked IL-1ra prodrug |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| KR102331820B1 (ko) | 2016-03-01 | 2021-11-29 | 아센디스 파마 본 디지즈 에이/에스 | Pth 프로드럭 |
| SG11201901576QA (en) * | 2016-09-29 | 2019-03-28 | Ascendis Pharma Bone Diseases As | Dosage regimen for a controlled-release pth compound |
| KR102611820B1 (ko) | 2016-09-29 | 2023-12-07 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
| CN115651056A (zh) | 2016-11-08 | 2023-01-31 | 里珍纳龙药品有限公司 | 类固醇类化合物及其蛋白质-偶联物 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
| EP3790899A1 (en) | 2018-05-09 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| JP7383703B2 (ja) * | 2018-09-26 | 2023-11-20 | アセンディス ファーマ エー／エス | 新規ヒドロゲルコンジュゲート |
| TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣３多肽之持續遞送 |
| IT201800009444A1 (it) * | 2018-10-15 | 2020-04-15 | Fidia Farm Spa | Coniugati tra acido ialuronico e amminobisfosfonati e loro impiego terapeutico |
| WO2020254609A1 (en) * | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Tyrosine kinase inhibitor conjugates |
| AU2021269007A1 (en) * | 2020-05-04 | 2022-11-24 | Ascendis Pharma A/S | Hydrogel irradiation |
| WO2023096899A1 (en) * | 2021-11-24 | 2023-06-01 | Amacathera | Hydrogel pharmaceutical compositions |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| HUP0102803A3 (en) * | 1998-06-30 | 2004-06-28 | Amgen Inc Thousand Oaks | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| AU2003226166A1 (en) | 2002-04-04 | 2003-10-20 | Enzon, Inc. | Polymeric acyl derivatives of indoles |
| SI1620118T1 (sl) | 2003-04-08 | 2014-11-28 | Yeda Research And Development Co., Ltd. | Reverzibilna pegilirana zdravila |
| US7842667B2 (en) | 2003-12-22 | 2010-11-30 | Regentis Biomaterials Ltd. | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
| KR101234476B1 (ko) * | 2004-03-05 | 2013-02-18 | 덴끼 가가꾸 고교 가부시키가이샤 | 히알루론산/메토트렉세이트 화합물 |
| ES2741524T3 (es) | 2004-03-23 | 2020-02-11 | Ascendis Pharma Gmbh | Profármaco polimérico con un enlazador autoinmolador |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| ITPD20050146A1 (it) * | 2005-05-20 | 2006-11-21 | Fidia Farmaceutici | Fillers riassorbibili costituiti da liposomi e acido ialuronico e o suoi derivati |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| MX2009008334A (es) | 2007-02-05 | 2009-08-12 | Nicox Sa | Esteroides que liberan oxido nitrico. |
| WO2009045539A2 (en) | 2007-10-05 | 2009-04-09 | Nektar Therapeutics Al, Corporation | Oligomer-corticosteroid conjugates |
| CN101980725B (zh) | 2008-02-01 | 2013-06-12 | 阿森迪斯药物股份有限公司 | 包含可自裂解的连接体的前药 |
| BRPI0911780B1 (pt) | 2008-04-29 | 2021-10-05 | Ascendis Pharma Endocrinology Division A/S | Composição farmacêutica compreendendo compostos peguilados de hormônio de crescimento humano recombinante, e profármaco |
| US20120058084A1 (en) | 2009-03-05 | 2012-03-08 | Ascendis Pharma As | Interferon Alpha Carrier Prodrugs |
| WO2011009047A2 (en) | 2009-07-16 | 2011-01-20 | Ta Tung Yuan | Il-1ra-polymer conjugates |
| NZ597960A (en) * | 2009-07-31 | 2013-07-26 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| EP2459227B1 (en) * | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
| EP2459225A1 (en) | 2009-07-31 | 2012-06-06 | Ascendis Pharma A/S | Carrier linked pramipexole prodrugs |
| WO2011089214A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| US9597412B2 (en) * | 2011-03-16 | 2017-03-21 | University Of Delaware | Injectable delivery system for heparan-binding growth factors |
-
2013
- 2013-10-08 MX MX2015004330A patent/MX363462B/es unknown
- 2013-10-08 US US14/435,367 patent/US10980860B2/en active Active
- 2013-10-08 EP EP13773786.2A patent/EP2906245B1/en active Active
- 2013-10-08 JP JP2015536099A patent/JP6355636B2/ja active Active
- 2013-10-08 BR BR112015007814-1A patent/BR112015007814B1/pt active IP Right Grant
- 2013-10-08 CN CN201380053348.0A patent/CN104755104A/zh active Pending
- 2013-10-08 SG SG11201501920PA patent/SG11201501920PA/en unknown
- 2013-10-08 RU RU2015117539A patent/RU2682676C2/ru active
- 2013-10-08 CA CA2885169A patent/CA2885169C/en active Active
- 2013-10-08 AU AU2013328774A patent/AU2013328774B2/en not_active Ceased
- 2013-10-08 WO PCT/EP2013/070949 patent/WO2014056915A1/en active Application Filing
- 2013-10-08 MY MYPI2015000831A patent/MY186106A/en unknown
-
2015
- 2015-03-10 IL IL237649A patent/IL237649B/en active IP Right Grant
- 2015-04-06 MX MX2019003249A patent/MX2019003249A/es unknown
- 2015-09-29 HK HK15109554.2A patent/HK1208813A1/xx unknown
- 2015-10-20 HK HK15110314.1A patent/HK1209618A1/xx unknown
-
2017
- 2017-12-13 AU AU2017276235A patent/AU2017276235A1/en not_active Abandoned
-
2018
- 2018-07-12 IL IL260579A patent/IL260579B/en active IP Right Grant
-
2019
- 2019-04-02 IL IL265774A patent/IL265774B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20150290337A1 (en) | 2015-10-15 |
| BR112015007814B1 (pt) | 2022-04-19 |
| MY186106A (en) | 2021-06-22 |
| AU2013328774B2 (en) | 2017-11-30 |
| AU2017276235A1 (en) | 2018-01-18 |
| AU2013328774A1 (en) | 2015-04-02 |
| EP2906245B1 (en) | 2021-01-13 |
| CA2885169C (en) | 2021-06-22 |
| IL237649B (en) | 2018-08-30 |
| MX2015004330A (es) | 2015-07-06 |
| SG11201501920PA (en) | 2015-04-29 |
| MX363462B (es) | 2019-03-25 |
| IL237649A0 (en) | 2015-04-30 |
| JP2015534571A (ja) | 2015-12-03 |
| IL265774A (en) | 2019-06-30 |
| WO2014056915A1 (en) | 2014-04-17 |
| JP6355636B2 (ja) | 2018-07-11 |
| HK1209618A1 (en) | 2016-04-08 |
| MX2019003249A (es) | 2019-07-04 |
| IL260579A (en) | 2018-10-31 |
| IL260579B (en) | 2019-05-30 |
| CA2885169A1 (en) | 2014-04-17 |
| EP2906245A1 (en) | 2015-08-19 |
| RU2015117539A (ru) | 2016-12-10 |
| IL265774B (en) | 2020-05-31 |
| RU2682676C2 (ru) | 2019-03-20 |
| CN104755104A (zh) | 2015-07-01 |
| BR112015007814A2 (pt) | 2017-07-04 |
| US10980860B2 (en) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265774B (en) | Diagnosis, prevention and treatment of joint diseases | |
| EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| AP2014007804A0 (en) | Compositions and methods for the treatment of hepatic diseases and disorders. | |
| EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
| HK1201045A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP3013425A4 (en) | Treatment and diagnosis of ocular disease | |
| HK1216721A1 (zh) | 治療肝臟疾病或病狀的用途和方法 | |
| IL234093A0 (en) | Preparations and dosages for oral administration and their uses for the treatment of Gaucher's disease | |
| EP2943593A4 (en) | DIAGNOSIS AND TREATMENT OF VIRUS DISEASES | |
| HK1223280A1 (zh) | 用於心力衰竭的預防或治療的人 | |
| HK1188565A1 (en) | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | |
| AU2012900775A0 (en) | Therapeutic and diagnostic agents | |
| GB201204744D0 (en) | Therapeutic and diagnostic target | |
| GB201204754D0 (en) | Therapeutic and diagnostic target | |
| GB201204664D0 (en) | Therapeutic and diagnostic target | |
| GB201204658D0 (en) | Therapeutic and diagnostic target | |
| GB201204578D0 (en) | Therapeutic and diagnostic target | |
| GB201204567D0 (en) | Therapeutic and diagnostic target | |
| GB201204561D0 (en) | Therapeutic and diagnostic target | |
| GB201204491D0 (en) | Therapeutic and diagnostic target | |
| GB201204483D0 (en) | Therapeutic and diagnostic target | |
| GB201204478D0 (en) | Therapeutic and diagnostic target | |
| GB201204389D0 (en) | Therapeutic and diagnostic target | |
| GB201204361D0 (en) | Therapeutic and diagnostic target |